Hysbysiad contract
Adran I:
Endid
contractio
I.1) Enw a chyfeiriad
The Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority")
Gyle Square (NSS Head Office), 1 South Gyle Crescent
Edinburgh
EH12 9EB
UK
Person cyswllt: Ruaridh Armitage
Ffôn: +44 1698794410
E-bost: ruaridh.armitage@nhs.scot
NUTS: UKM
Cyfeiriad(au) rhyngrwyd
Prif gyfeiriad: http://www.nhsscotlandprocurement.scot.nhs.uk/
Cyfeiriad proffil y prynwr: http://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA11883
I.2) Caffael ar y cyd
Caiff y contract ei ddyfarnu gan gorff prynu canolog
I.3) Cyfathrebu
Mae'r dogfennau caffael ar gael ar gyfer mynediad uniongyrchol anghyfyngedig a llawn, yn rhad ac am ddim ar:
https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html
Gellir cael gwybodaeth ychwanegol o'r cyfeiriad uchod
Rhaid anfon tendrau neu geisiadau i gymryd rhan yn electronig at:
https://www.publictendersscotland.publiccontractsscotland.gov.uk/web/login.html
I.4) Y math o awdurdod contractio
Corff a lywodraethir gan gyfraith gyhoeddus
I.5) Prif weithgaredd
Iechyd
Adran II: Gwrthrych
II.1) Cwmpas y caffaeliad
II.1.1) Teitl
Contrast Media Agents
Cyfeirnod: NP35424
II.1.2) Prif god CPV
33600000
II.1.3) Y math o gontract
Cyflenwadau
II.1.4) Disgrifiad byr
This Framework Agreement is for the supply of Contrast Media Agents to NHS Scotland.
The Goods have been separated into eight (8) categories, each of which is identified as a “Lot”.
Full details of each Lot is contained in section II.2 of this Notice.
II.1.5) Cyfanswm gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 44 036 295.00 GBP
II.1.6) Gwybodaeth am lotiau
Mae’r contract hwn wedi’i rannu’n lotiau:
Ydy
Gellir cyflwyno tendrau ar gyfer pob lot
II.2) Disgrifiad
Rhif y Lot 1
II.2.1) Teitl
Lot 1 – Barium Based Contrast Agents
II.2.2) Cod(au) CPV ychwanegol
33600000
II.2.3) Man cyflawni
Cod NUTS:
UKM
Prif safle neu fan cyflawni:
All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Disgrifiad o’r caffaeliad
Supply of Barium Based Contrast Agents to NHS Scotland. The Authority intends awarding all presentations within this lot as an unranked multi-supplier. Full details can be found within the ITT.
II.2.5) Meini prawf dyfarnu
Maen prawf isod:
Maes prawf ansawdd: Contingency Planning
/ Pwysoliad: 10
Maes prawf ansawdd: Sustainability
/ Pwysoliad: 5
Maes prawf ansawdd: Product Support
/ Pwysoliad: 5
Price
/ Pwysoliad:
80
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 364 550.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Hyd mewn misoedd: 36
Gall y contract hwn gael ei adnewyddu: Ydy
Disgrifiad o’r adnewyddiadau:
The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Na
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 2
II.2.1) Teitl
Lot 2 – Ultrasound Contrast Agents
II.2.2) Cod(au) CPV ychwanegol
33600000
II.2.3) Man cyflawni
Cod NUTS:
UKM
Prif safle neu fan cyflawni:
All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Disgrifiad o’r caffaeliad
Supply of Ultrasound Contrast Agents to NHS Scotland. The Authority intends awarding all presentations within this lot as an unranked multi-supplier. Full details can be found within the ITT.
II.2.5) Meini prawf dyfarnu
Maen prawf isod:
Maes prawf ansawdd: Contingency Planning
/ Pwysoliad: 10
Maes prawf ansawdd: Sustainability
/ Pwysoliad: 5
Maes prawf ansawdd: Product Support
/ Pwysoliad: 5
Price
/ Pwysoliad:
80
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 263 070.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Hyd mewn misoedd: 36
Gall y contract hwn gael ei adnewyddu: Ydy
Disgrifiad o’r adnewyddiadau:
The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Na
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 3
II.2.1) Teitl
Lot 3 – Macrocyclic Gadolinium Based Contrast Agents
II.2.2) Cod(au) CPV ychwanegol
33600000
II.2.3) Man cyflawni
Cod NUTS:
UKM
Prif safle neu fan cyflawni:
All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Disgrifiad o’r caffaeliad
Supply of Macrocyclic Gadolinium Based Contrast Agents to NHS Scotland. The Authority intends awarding all presentations within this lot as an unranked multi-supplier. Full details can be found within the ITT.
II.2.5) Meini prawf dyfarnu
Maen prawf isod:
Maes prawf ansawdd: Contingency Planning
/ Pwysoliad: 10
Maes prawf ansawdd: Sustainability
/ Pwysoliad: 5
Maes prawf ansawdd: Product Support
/ Pwysoliad: 5
Price
/ Pwysoliad:
80
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 18 423 225.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Hyd mewn misoedd: 36
Gall y contract hwn gael ei adnewyddu: Ydy
Disgrifiad o’r adnewyddiadau:
The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Na
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 4
II.2.1) Teitl
Lot 4 – Linear Gadolinium Based Contrast Agents
II.2.2) Cod(au) CPV ychwanegol
33600000
II.2.3) Man cyflawni
Cod NUTS:
UKM
Prif safle neu fan cyflawni:
All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Disgrifiad o’r caffaeliad
Supply of Linear Gadolinium Based Contrast Agents to NHS Scotland. The Authority intends awarding all presentations within this lot as an unranked multi-supplier. Full details can be found within the ITT.
II.2.5) Meini prawf dyfarnu
Maen prawf isod:
Maes prawf ansawdd: Contingency Planning
/ Pwysoliad: 10
Maes prawf ansawdd: Sustainability
/ Pwysoliad: 5
Maes prawf ansawdd: Product Support
/ Pwysoliad: 5
Price
/ Pwysoliad:
80
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 1 782 150.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Hyd mewn misoedd: 36
Gall y contract hwn gael ei adnewyddu: Ydy
Disgrifiad o’r adnewyddiadau:
The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Na
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 5
II.2.1) Teitl
Lot 5 – Non-ionic Monomeric Iodine Based Contrast Agents
II.2.2) Cod(au) CPV ychwanegol
33600000
II.2.3) Man cyflawni
Cod NUTS:
UKM
Prif safle neu fan cyflawni:
All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Disgrifiad o’r caffaeliad
Supply of Non-ionic Monomeric Iodine Based Contrast Agents to NHS Scotland. The Authority intends awarding all presentations within this lot as an unranked multi-supplier. Full details can be found within the ITT.
II.2.5) Meini prawf dyfarnu
Maen prawf isod:
Maes prawf ansawdd: Contingency Planning
/ Pwysoliad: 10
Maes prawf ansawdd: Sustainability
/ Pwysoliad: 5
Maes prawf ansawdd: Product Support
/ Pwysoliad: 5
Price
/ Pwysoliad:
80
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 21 260 500.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Hyd mewn misoedd: 36
Gall y contract hwn gael ei adnewyddu: Ydy
Disgrifiad o’r adnewyddiadau:
The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Na
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 6
II.2.1) Teitl
Lot 6 – Non-Ionic Dimeric Iodine Based Contrast Agents
II.2.2) Cod(au) CPV ychwanegol
33600000
II.2.3) Man cyflawni
Cod NUTS:
UKM
Prif safle neu fan cyflawni:
All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Disgrifiad o’r caffaeliad
Supply of Non-Ionic Dimeric Iodine Based Contrast Agents to NHS Scotland. The Authority intends awarding all presentations within this lot as an unranked multi-supplier. Full details can be found within the ITT.
II.2.5) Meini prawf dyfarnu
Maen prawf isod:
Maes prawf ansawdd: Contingency Planning
/ Pwysoliad: 10
Maes prawf ansawdd: Sustainability
/ Pwysoliad: 5
Maes prawf ansawdd: Product Support
/ Pwysoliad: 5
Price
/ Pwysoliad:
80
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 1 110 275.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Hyd mewn misoedd: 36
Gall y contract hwn gael ei adnewyddu: Ydy
Disgrifiad o’r adnewyddiadau:
The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Na
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 7
II.2.1) Teitl
Lot 7 – Non-Ionic Monomer Iomeprol Contrast Agents
II.2.2) Cod(au) CPV ychwanegol
33600000
II.2.3) Man cyflawni
Cod NUTS:
UKM
Prif safle neu fan cyflawni:
All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Disgrifiad o’r caffaeliad
Supply of Non-Ionic Monomer Iomeprol Contrast Agents to NHS Scotland. The Authority intends awarding all presentations within this lot as an unranked multi-supplier. Full details can be found within the ITT.
II.2.5) Meini prawf dyfarnu
Maen prawf isod:
Maes prawf ansawdd: Contingency Planning
/ Pwysoliad: 10
Maes prawf ansawdd: Sustainability
/ Pwysoliad: 5
Maes prawf ansawdd: Product Support
/ Pwysoliad: 5
Price
/ Pwysoliad:
80
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 439 045.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Hyd mewn misoedd: 36
Gall y contract hwn gael ei adnewyddu: Ydy
Disgrifiad o’r adnewyddiadau:
The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Na
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 8
II.2.1) Teitl
Lot 8 – Additional Iodine Based Contrast Agents
II.2.2) Cod(au) CPV ychwanegol
33600000
II.2.3) Man cyflawni
Cod NUTS:
UKM
Prif safle neu fan cyflawni:
All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Disgrifiad o’r caffaeliad
Supply of Additional Iodine Based Contrast Agents to NHS Scotland. The Authority intends awarding all presentations within this lot as an unranked multi-supplier. Full details can be found within the ITT.
II.2.5) Meini prawf dyfarnu
Maen prawf isod:
Maes prawf ansawdd: Contingency Planning
/ Pwysoliad: 10
Maes prawf ansawdd: Sustainability
/ Pwysoliad: 5
Maes prawf ansawdd: Product Support
/ Pwysoliad: 5
Price
/ Pwysoliad:
80
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 393 480.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Hyd mewn misoedd: 36
Gall y contract hwn gael ei adnewyddu: Ydy
Disgrifiad o’r adnewyddiadau:
The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Na
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Section III: Gwybodaeth gyfreithiol, economaidd, ariannol a thechnegol
III.1) Amodau ar gyfer cymryd rhan
III.1.3) Gallu technegol a phroffesiynol
Rhestr a disgrifiad byr o’r meini prawf dethol:
(a) Potential Framework Participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation (PL, PLGB or PLPI number) that has been approved by the MHRA for all tendered Medicines at the date of submission of the tender.
(b) Potential Framework Participants and any sub-contractor(s) must possess valid certification of BS EN ISO 9001 or equivalent.
(c) All tendered Goods must comply with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency ("NPSA") Guidelines on Packaging and Labelling on pack design.
(d) Potential Framework Participants are required to provide evidence that their organisation has taken steps to build their awareness of the climate change emergency and how they will respond.
Lefel(au) gofynnol y safonau sydd eu hangen:
a) Confirmation of existence of a valid and current UK Marketing Authorisation (PL, PLGB or PLPI number) that has been approved by the MHRA for all tendered Medicines at the date of submission of the tender should be included in the Qualification Envelope of the ITT under the Technical and Professional ability: Quality Control.
(b) Confirmation of the existence of valid certification of BS EN ISO 9001 or equivalent. Confirmation of such certification should be included in the Qualification Envelope of the ITT under the Quality Assurance Schemes.
(c) Confirmation that samples for tendered Goods will be supplied upon request to ensure compliance with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency ("NPSA") Guidelines on Packaging and Labelling on pack design. Confirmation of sample provision should be provided in the Qualification Envelope of the ITT under Technical and Professional ability: Products.
(d) A completed copy of the Bidder Climate Change Plan Template, including planned projects and actions to reduce the bidder’s carbon emissions should be provided in the Qualification Envelope of the ITT under Environmental Management Criteria. This does not need to contain calculated carbon emissions.
III.2) Amodau sy’n gysylltiedig â’r contract
Section IV: Gweithdrefn
IV.1) Disgrifiad
IV.1.1) Y math o weithdrefn
Gweithdrefn agored
IV.1.3) Gwybodaeth am gytundeb fframwaith neu system brynu ddynamig
The procurement involves the establishment of a framework agreement with several operators.
IV.1.6) Gwybodaeth am arwerthiant electronig
Defnyddir arwerthiant electronig
IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)
The procurement is covered by the Government Procurement Agreement:
Ydy
IV.2) Gwybodaeth weinyddol
IV.2.2) Terfyn amser i dendrau neu geisiadau i gymryd rhan ddod i law
Dyddiad:
30/05/2024
Amser lleol: 12:00
IV.2.4) Ym mha iaith/ieithoedd y gellir cyflwyno tendrau neu geisiadau i gymryd rhan
EN
IV.2.6) Yr isafswm cyfnod gofynnol i’r sawl sy’n tendro gynnal y tendr
Hyd mewn misoedd: 3 (o’r dyddiad a nodwyd i dendr ddod i law)
IV.2.7) Amodau ar gyfer agor tendrau
Dyddiad:
30/05/2024
Amser lleol: 12:00
Section VI: Gwybodaeth ategol
VI.1) Gwybodaeth am ailddigwydd
Caffaeliad cylchol yw hwn:
Na
VI.2) Gwybodaeth am lifau gwaith electronig
Defnyddir archebion electronig
Derbynnir anfonebau electronig
Defnyddir taliadau electronig
VI.3) Gwybodaeth ychwanegol
The estimated value referred to in Section II.I.5 and within each Lot covers the thirty-six (36) months contract duration and the full twenty-four (24) months extension options.
The buyer is using PCS-Tender to conduct this ITT exercise. The Project code is 26405. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2343
A sub-contract clause has been included in this contract. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2363
Community benefits are included in this requirement. For more information see: https://www.gov.scot/policies/public-sector-procurement/community-benefits-in-procurement/
A summary of the expected community benefits has been provided as follows:
It is a mandatory requirement that Potential Framework Participants agree to support the concept, provision and ongoing development of community benefits provision in relation to this framework.
Potential Framework Participants are required to agree to this mandatory requirement. They are also requested to provide a brief summary of the community benefits that have recently been delivered within Scotland, if at all, and also what impact and outcomes these have achieved.
Potential Framework Participants are required to summarise any proposed community benefits that will be developed and delivered as part of this contract if successful or, alternatively, Potential Framework Participants confirm that they will engage with the NHS Scotland’s Community Benefits Gateway (CBG). This gateway, developed through requests from suppliers seeking opportunities to support the delivery of community benefits within the contracting region, provides information on community benefit opportunities. The CBG is a free and easy to use online service that connects NHS Scotland suppliers with third sector community organisations within Scotland and will be used for tracking and reporting and is an approved compliant route to the realisation of community benefits.
For further information please visit www.nss.nhs.scot/procurement-and-logistics/sustainability/access-our-community-benefit-gateway
(SC Ref:764884)
VI.4) Gweithdrefnau adolygu
VI.4.1) Corff adolygu
Edinburgh Sheriff Court
Sheriff Court House, 27 Chambers Street
Edinburgh
EH1 1LB
UK
Ffôn: +44 1312252525
E-bost: edinburgh@scotcourts.gov.uk
Cyfeiriad(au) rhyngrwyd
URL: https://www.scotcourts.gov.uk/the-courts/court-locations/edinburgh-sheriff-court-and-justice-of-the-peace-court
VI.4.3) Gweithdrefn adolygu
Gwybodaeth fanwl gywir am y terfyn(au) amser ar gyfer gweithdrefnau adolygu:
The Authority will notify economic operators who submitted a tender or (where no deselection notification has previously been made) applied to be selected to tender, of its decision to award the framework agreement which notification will contain among other information, a summary of the reasons why the economic operator was unsuccessful. The notification will incorporate a 'standstill period' of a minimum of 10 clear calendar days (or a minimum of 15 if the communication method used is not electronic) between the date on which the Authority despatches the notice(s) and the date on which the Authority proposes to conclude the relevant framework agreement. The bringing of court proceedings against the Authority during the standstill period will automatically continue the prohibition on entering into the framework agreement until the court proceedings are determined, discontinued or disposed of, or the court, by interim order, brings to an end the prohibition. The remedies that may be awarded by the courts before the framework agreement has been entered into include the setting aside of the decision to award the framework agreement to the winning tenderer(s). The bringing of court proceedings against the Authority after the framework agreement has been entered into will not affect the framework agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise the remedies that may be awarded by the courts where the framework agreement has been entered into are limited to the award of damages.
VI.5) Dyddiad anfon yr hysbysiad hwn
30/04/2024